

Name	Personal financial – personal payment received (including shareholdings and expenses and hospitality beyond reasonably required)		Non-personal financial – payment/benefit that benefits a department or organisation individual has managerial responsibility (including fellowships, grants etc.)		Personal non-financial (including, opinions, holding office in professional organisation)	Date declared
	Specific: payment relates to manufacturer/owner of product/service	Non-specific: payment relates to industry/sector product/service comes from	Specific – payment relates to manufacturer/owner of product/service	Non-specific – payment relates to industry/sector product/service comes from		
Alison Allam	n/a	n/a	n/a	n/a	n/a	21.11.14
Harry Allen	n/a	n/a	n/a	n/a	n/a	10.11.14
Moyra Amess	n/a	n/a	n/a	n/a	n/a	3.8.14 (Reviewed and confirmed 17.11.14)
Jane Bradshaw	n/a	n/a	n/a	n/a	n/a	30.12.14
Allison Duggal	n/a	n/a	n/a	Performs external quality assurance visits for Antenatal and Newborn Screening and diabetic Eye Screening for Public Health England. Employer is reimbursed for her time.		11.11.14
Tim Fielding	n/a	n/a	n/a	n/a	n/a	7.11.14
Frances Garraghan	n/a	n/a	n/a	n/a	n/a	20.11.14
Zoe Goodacre	n/a	n/a	n/a	n/a	n/a	7.11.14
Nicola Hobbs	n/a	n/a	n/a	n/a	n/a	21.01.15
Roger Hughes	n/a	n/a	n/a	n/a	n/a	20.11.14
John Jolly	n/a	CEO of 'Blenheim' drug and alcohol charity. Blenheim is a member of Hep C coalition and in that capacity John is involved in efforts to increase treatment of Hep C and the introduction of new drugs for the treatment of hep c. The secretariat is funded by Gilead. I receive no money outside of my role at Blenheim, research interests and involvement would be also in the context of my role at Blenheim rather than in any private capacity.	n/a	n/a	I chair the Naloxone Action Group which is campaigning for the increased use of Naloxone for those at risk of overdose on opiate medication or using illicitly.	10.11.14
Damien Longson	n/a	Family member is employee of NICE. Director of Research and Innovation Manchester Mental Health & Social Care Trust.	n/a	n/a	n/a	04.01.15
Rubin Minhas	n/a	n/a	n/a	n/a	Member of Ethics Committees for BMJ and Dr Foster. Expert advisory body member MHRA.	6.11.14
Julie Rigby	n/a	n/a	n/a	n/a	n/a	19.11.14

Alaster Rutherford		Director of Rutherford Health Consulting Ltd which provides/provided expert pharmacist services to Bath & NESomerset CCG, SW CSU, NICE, Bath University, HCPC and other NHS bodies. Fee received from Shire Pharmaceuticals for an implementation project involving a positive NICE technology appraisal (TA211). Director of Verto Health Consulting Ltd joint venture which has received one payment from Astellas Pharma for the assessment of a budget impact tool linked to the implementation of NICE clinical guideline (CG97 – Lower Urinary Tract Symptoms). Wife is the owner and sole director of Banwell Village Pharmacy Limited which provides NHS Community Pharmacy Services in Banwell, North Somerset				
	n/a		n/a	n/a	n/a	12.11.14
Michael Varrow	n/a	n/a	n/a	n/a	n/a	10.11.14
John Walker	n/a	n/a	n/a	n/a	n/a	20.11.14
David Weaver	n/a	n/a	n/a	n/a	n/a	1.8.14
Asma Khalil		Collaboration with commercial companies, such as USCOM [*] , Roche Diagnostics [*] , Alere Diagnostics [*] and proact medical Ltd [*] (research equipment and/or consumables)			<p>Member of the National Clinical Reference Group for Fetal Medicine, Co-chair of the “Improving Outcomes” working group, South West London Maternity Network, • Associate Editor for the journal Biomedical Central, • Assistant Convenor for the MRCOG Part1 course, RCOG</p> <p>• Principal Investigator at St George’s Hospital for several NIHR funded studies, e.g. Non-invasive Prenatal Testing (NIPT)</p> <p>• Reviewer for the National Maternal Near-miss Surveillance Programme (UKNes)</p> <p>• Chief Investigator for Cardiovascular changes in Pregnancy (CVP) study and Quantitative fetal fibronectin, Cervical length and ActimPartus® for the prediction of Preterm birth in Symptomatic women (QFCAPS)</p> <p>Pregnancy and Childbirth</p> <p>• Member of the Maternal and Fetal Medicine National Clinical Study Group</p>	16.02.15